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ABSTRACT  
 
Background: Neuromyelitis optica spectrum disorders (NMOSD) are characterized by 
severe optic neuritis and/or longitudinally extensive transverse myelitis with 3 or more 
vertebral segments, and some characteristic brain lesions. Serum autoantibodies against 
aquaporin-4 (AQP4) are detected in more than half of NMOSD cases. However, some 
NMOSD patients remain seronegative despite repetitive testing during attacks with 
highly sensitive cell-based assays (CBA). Recently, a few NMOSD cases with 
antibodies against myelin oligodendrocyte glycoprotein (MOG) have been described, 
but the frequency of MOG-antibodies or clinical features that can differentiate them 
from those with AQP4-antibodies or seronegatives have not been analyzed. 
Objectives: To evaluate clinical features and treatment response among patients with 
neuromyelitis optica spectrum disorders (NMOSD) who have serum autoantibodies 
against myelin oligodendrocyte glycoprotein (MOG), aquaporin-4 (AQP4), and 
seronegative for both antibodies.  
Methods: Sera from patients diagnosed of NMOSD in one of three centers (two in 
Brazil, one in Japan) were tested for MOG antibodies using HEK293 cells transiently 
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transfected with a plasmid containing full-length MOG and for AQP4 antibodies using 
HEK293 cells transfected with AQP4 M23-isoform CBA with live transfected cells.  
Results: Among the 215 NMOSD patients, 7.4% (16/215) were positive for MOG 
antibodies, and 64.7% (139/215) were positive for AQP4 antibodies. No patients were 
positive for both antibodies. Patients with MOG antibodies represented 21.1% (16/76) 
of the patients negative for AQP4 antibodies. Compared with patients with AQP4 
antibodies or patients who were seronegative, patients with MOG antibodies were more 
frequently male, had a more restricted phenotype (optic neuritis more common than 
myelitis), more frequently had bilateral simultaneous optic neuritis, had more often a 
single-attack, had caudal myelitis, have less concomitant autoimmunity, and usually 
demonstrated better functional recovery after treatment with high-dose intravenous 
corticosteroids for acute attacks.  
Conclusions: NMOSD patients with MOG antibodies have distinct clinical features, 
fewer attacks, and better recovery than patients with AQP4 antibodies or patients 
seronegative for both antibodies. These findings suggest that immune mechanisms 
involved in each of those groups may be distinct, indicating that the long-term 
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management and prognosis of patients with MOG-antibodies may be different from 
those with AQP4-antibodies or seronegatives for both antibodies. 
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1. INTRODUCTION 
 
Neuromyelitis optica (NMO) is an inflammatory disease from the central 
nervous system (CNS) characterized by severe attacks of optic neuritis (ON) and 
longitudinally extensive transverse myelitis (LETM) with spinal cord lesions extending 
for three or more sagittal vertebral segments observed on the magnetic resonance 
imaging (MRI)1). The current diagnostic criteria for definitive NMO requires the 
presence of both ON and myelitis2). Limited forms of the disease are known as NMO 
spectrum disorders (NMOSD). NMOSD currently includes patients with either ON or 
LETM (single or recurrent events of LETM or recurrent or simultaneous bilateral ON)3) 
as illustrated in the figure 1.  
Historically, Giovanni Battista Pescetto reported the first description 
suggestive of NMO in 18444), but it was only in 1894 that the French physician Eugène 
Devic published the famous case report5) and his student Fernand Gault first used the 
term neuromyelitis optica (neuro-myélite optique) on his doctoral thesis that included 
pathological analysis6). Interestingly, more than half of the patients from Lyon were 
males, 82.4% (14/17) of the cases were monophasic (i.e. simultaneous ON and myelitis), 
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88.2% (15/17) had bilateral ON and 29.4% (5/17) had brain or brainstem lesions6, 7). 
Thereafter, several definitions of NMO (considered by that time a variant of multiple 
sclerosis) published prior to AQP4 antibody discovery are summarized on the Table 18). 
Serum antibodies against aquaporin-4 (AQP4) are present only in the serum 
of NMOSD patients and its discovery ten years ago clearly segregated NMOSD from 
multiple sclerosis (MS)9). The primary target for these autoantibodies is the AQP4, a 
bidirectional transmembrane water channel richly expressed in the endfeet of 
astrocytes10). Human AQP4 is expressed in two functional isoforms, known as M1 (34 
kDa) and M23 (32 kDa; having a 22 amino acids shorter N-terminus). Both AQP4 
isoforms are able to form tetramers, but only M23 assembles into large orthogonal array 
of particles (OAP)11). The formation of OAPs seems to be important to increase the 
binding ability of AQP4 antibodies due to the formation of large antigen 
supra-molecular structures. AQP4 antibodies seems to be pathogenic immunoglobulin 
G (IgG) 1 subclass antibodies, and they are able to promote efficient antibody- and 
complement-dependent cell-mediated cytotoxicity causing severe astrocyte injury (see 
schematic illustration in the figure 2) demonstrated on in-vitro, animal and human 
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pathological studies12-16), and glial fibrillary acidic protein (GFAP - an astrocyte 
marker) in the cerebrospinal fluid (CSF) of patients with AQP4 antibodies is 
remarkably elevated during NMO attacks 17). Taken together, these findings strongly 
suggest that NMOSD patients with AQP4 antibodies is an antibody-mediated 
astrocytopathy 18). 
Approximately 90% of the NMO patients and more than half of the NMOSD 
patients are positive for autoantibodies against aquaporin-4 (AQP4)19, 20). After the 
discovery of AQP4 antibody, the clinical manifestation of those patients is increasingly 
recognized as heterogeneous and includes many types of brain lesions preferentially 
localized in regions with high-expression of AQP421, 22), and not restricted anymore to 
attacks involving solely the optic nerve and spinal cord. The patients with AQP4 
antibodies have a strong female predominance, onset ages concentrated in the fourth 
decade, high risk of further attacks, and permanent disability. Therefore, patients 
positive for AQP4 antibodies require early identification to avoid exposition of patients 
to invasive diagnostic procedures such as biopsies23) and receive appropriate 
immunosuppressive treatment24). More recently, we have reported patients with AQP4 
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antibodies that do not fulfill the current criteria for NMOSD25), such as monophasic 
unilateral ON with poor recovery, recurrent short myelitis (i.e. with less than 3 vertebral 
segments on the sagittal view), and recurrent attacks restricted to brainstem, indicating 
that a broaden disease diagnostic criteria incorporating the AQP4 antibody as a major 
biomarker may be warranted. However, a proportion of the patients diagnosed with 
NMO or NMOSD remains negative for AQP4 antibodies despite the use of the best 
assays available on serum samples collected during an acute attack before any treatment. 
Therefore, the application of this disease model centered on the AQP4 antibodies 
mediated astrocyte injury to all NMO patients is challenged by the fact that some cases 
remain AQP4 antibody negative. 
Recently, autoantibodies against myelin oligodendrocyte glycoprotein (MOG) 
were reported in four patients who were clinically diagnosed with NMOSD and 
negative for AQP4 antibodies26). MOG is a glycoprotein with 26 – 28 kDa, and is a 
member of the immunoglobulin superfamily with a single extracellular 
immunoglobulin-like variable domain27). MOG is expressed only in the CNS on the 
outermost lamellae of the myelin sheath as well as the cell body and processes of 
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oligodendrocytes in a head-to-tail dimeric form28). The amino acid sequence of MOG is 
highly conserved among animal species (>90%), and this is indicative of an important 
biological function29). The expression of MOG lately in the developmental stage of 
CNS correlates with the later stages of myelinogenesis, suggesting that MOG has a role 
in the completion, compaction, and/or maintenance of myelin. In addition, MOG may 
also have an immune-related function because it binds C1q, and thus could have 
regulatory functions of the classical complement pathway30). 
The localization of MOG on the surface of the myelin makes it accessible to 
autoantibodies (see schematic illustration in the figure 3). Many experimental 
autoimmune encephalomyelitis (EAE) models use MOG derived antigens to induce 
demyelination in mice. MOG-specific T cell receptor transgenic (usually known as 
TCRMOG or 2D2) C57BL/6 mice spontaneously develop an EAE-like neurological 
syndrome that resembles NMO31), and double transgenic animals originated from 2D2 
and MOG-specific Ig heavy-chain knock-in (known as IgHMOG) have severe EAE 
compared to single transgenic mice and MOG antibodies with immunoglobulin M 
(IgM) class switched to IgG132). MOG antibodies that recognize conformational 
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epitopes seems to be clinically relevant and they are detected by methods using folded 
(non-denaturated) protein preserving three-dimensional characteristics, in contrast to 
results obtained with assays based on denatured MOG (e.g. ELISA)33). Conformational 
sensitive MOG antibodies are found in brain tissue derived from patients with 
inflammatory CNS demyelinating diseases34). High-titer MOG antibodies in human 
serum samples are reported to be predominantly of the IgG1 subtype and efficiently 
mediate complement-dependent cytotoxicity in vitro35). However, none of these 
previous studies investigated comprehensively the features that may distinguish patients 
with AQP4 antibodies from those with high-titer MOG antibodies or those who are 
negative for both antibodies, even though such information is useful for clinical practice 
as patients who are seropositive for different antibodies may have different underlying 
physiopathology and prognosis. 
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2. OBJECTIVES 
 
In this study, the clinical, MRI and laboratory (other serum antibodies and 
CSF) characteristics of patients with high-titer MOG antibodies were compared with 
those of patients with AQP4 antibodies and patients who were seronegative for both 
antibodies. In addition, treatments used during acute attacks and at remission phase, and 
functional recovery after attacks were also compared among the three groups. 
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3. MATERIAL AND METHODS 
 
3.1 Patients and serum samples 
A total of 215 patients were included from three tertiary centers for this study: 
1) Hospital das Clínicas, Faculty of Medicine, University of Sao Paulo, Sao Paulo, 
Brazil; 2) Center for the Investigation of Multiple Sclerosis at Federal University of 
Minas Gerais, Belo Horizonte, Brazil; and 3) Tohoku University Hospital, Tohoku 
University School of Medicine, Sendai, Japan. Pediatric and adult patients who had 
received a clinical diagnosis of definitive NMO fulfilling Wingerchuk revised criteria2) 
or NMOSD were enrolled, which currently includes patients with one attack or 
recurrent LETM and those patients with bilateral simultaneous and/or recurrent ON. For 
simplicity, the term NMOSD is used to encompass both NMO and NMOSD. Only 
consecutive patients followed up in one of the three centers were included, and for 
whom adequate information regarding the clinical attacks, brain and spinal cord MRIs, 
and serum for antibody testing were available; seven patients were excluded because of 
a lack of information (five patients with AQP4 antibodies and two seronegative 
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patients). Demographic and clinical data was reviewed such as onset age, gender, 
ethnical background (self-declared), first attack site, number of attacks and their clinical 
characteristics, the presence of severe visual disability (visual acuity < 20/200), 
disability measured by the expanded disability status scale (EDSS), and treatments. 
Information regarding brain MRI from all patients and spinal cord MRI was required 
from those with symptoms suggestive of myelitis (patients with disease restricted to 
optic nerve had only brain and orbital MRI, as per routine clinical investigation). 
Results from the cerebrospinal fluid analysis and the positivity to other autoantibodies 
such as anti-nuclear antibody (ANA), anti-SSA antibody, anti-SSB antibody, 
anti-thyroglobulin antibody (TGAb), anti-thyroperoxidase antibody (TPOAb) was 
reviewed in all patients. All patients seronegative for both AQP4 and MOG antibodies 
were fully investigated, and alternative diagnoses like MS and other inflammatory CNS 
diseases were ruled out before inclusion in the study. The serum samples from the two 
Brazilian centers were stored at -80°C after centrifugation in each center, shipped on 
dry ice to the Department of Neurology, Tohoku University School of Medicine (Sendai, 
Japan), and stored again upon arrival at -80°C until analysis.  
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3.2 AQP4 antibody cell-based assay 
All serum samples were analyzed centrally at Tohoku University School of 
Medicine (Sendai, Japan) to detect AQP4 antibodies. The cell-based assay (CBA) for 
AQP4 antibody detection in living cells has been previously described25) using 
HEK-293 cells stably transfected with the M23 isoform of AQP4. In brief, AQP4-M23 
isoform or vector stably transfected cells after selection with G-418 600 mg/ml 
(Sigma-Aldrich, Saint Louis, MO, USA) were detached using a trypsin solution (trypsin 
0.1% + EDTA 0.02%), suspended in Dubecco’s Modified Eagle Medium (DMEM 1x) 
with 10% fetal bovine serum (FBS), centrifuged once and supernatant discarded. The 
cell pellet was resuspended in DMEM with 10% FBS and the concentration adjusted to 
4 x 105 cells/mL prior to the transfer of cells to each pre-coated slide glass chamber. On 
the next day, transfected cells were exposed to 1:4 diluted serum for 30 minutes at room 
temperature, washed twice with phosphate buffered saline (PBS) and exposed to goat 
anti-human IgG labeled with Alexafluor-488 (Invitrogen, Carlsbad, CA, USA) at 1:250 
dilution for 30 minutes at room temperature, washed 3 times with PBS and then fixed 
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with 4% formaldehyde for 15 minutes. Positivity was evaluated by the observation of 
green fluorescence signal (indicating the binding of IgG and labeled secondary 
anti-human IgG antibody) in the membrane of AQP4-M23 transfected cells that was 
absent in the vector-transfected cells. The titers were calculated semi-quantitatively 
using consecutive two-fold end-point dilutions.  
 
3.3 MOG antibody cell-based assay 
As described for AQP4 antibodies, all serum samples were analyzed centrally 
at Tohoku University School of Medicine (Sendai, Japan). The same samples screened 
for AQP4 antibodies were also analyzed for the presence of MOG antibodies using a 
CBA with live HEK-293 cells transiently transfected with a bicistronic plasmid vector 
(pIRES2-Dsred2 vector, BD Biosciences, San Jose, CA, USA; kindly provided by 
Patrick Joseph Waters, Oxford University, UK) containing full-length human MOG 
cDNA using the Fugene 6 transfection agent (Promega Corp, Madison, WI, USA) 
following manufacturer’s instructions at 1:3 ratio (6 µL DNA : 18 µL Fugene 6) added 
to 576 µL of low serum medium Opti-MEM I (Invitrogen, Carlsbad, CA, USA). After 
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15 minutes of incubation to form the transfection complex, the solution (total = 600 µL) 
was applied carefully on the 10 cm diameter cell culture dish with HEK293 cells (60 – 
70% confluent) and transfection efficiency was checked after 24 hours by direct 
microscopy visualization of red protein (ds-red2) expression. Cells were detached using 
a trypsin solution (trypsin 0.1% + EDTA 0.02%), suspended in DMEM with 10% FBS, 
centrifuged once and supernatant discarded. The cell pellet was resuspended in DMEM 
with 10% FBS and the concentration adjusted to 4 x 105 cells/mL prior to the transfer of 
cells to each pre-coated slide glass chamber. On the next day, transfected cells were 
exposed to patients’ diluted serum at 1:128 for 30 minutes at room temperature, washed 
twice with phosphate buffered saline (PBS), and then exposed for 30 minutes to 1:500 
diluted goat anti-human IgG labeled with Alexafluor-488, and cells were washed three 
times and then fixed with 4% formaldehyde for 15 minutes. Positivity was evaluated by 
the observation of green fluorescence signal (indicating the binding of IgG and labeled 
secondary anti-human IgG antibody) in the membrane of MOG transfected cells that 
was absent in the vector-transfected cells. In order to reduce the impact of transfection 
efficiency in the results, the samples were tested for MOG antibodies at least twice at a 
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dilution of 1:128 (the dilution with the best signal-to-noise ratio), and only patients 
whose samples were consistently judged to be positive were considered positive with 
high titers (see figure 4). The titers were calculated semi-quantitatively using 
consecutive two-fold end-point dilutions, so each sample was exposed to 
MOG-transfected cells at least three times in total. Later, positivity for the MOG 
antibodies was also confirmed at Oxford University in a blinded fashion. 
The cell-based assay for the MOG-antibodies was validated using 20 controls 
[10 healthy volunteers, and 10 patients with non-inflammatory CNS diseases 
(amyotrophic lateral sclerosis, Parkinson disease, spinocerebellar ataxia)], 98 patients 
with multiple sclerosis (MS) and 12 patients with acute disseminated encephalomyelitis 
(ADEM). None of the controls, 5/98 of the patients with MS (5.1%), and 5/12 of the 
patients with ADEM (41.7%) were positive for MOG antibodies using the full-length 
MOG assay with titers ≥ 1:128. The staining was compared with vector- and 
AQP4-transfected cells. Considering that MOG antibodies have been reported to be 
clinically relevant at high titers, the 1:128 dilution was used for the current study.  
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3.4 Statistical analysis 
Non-parametric tests (Wilcoxon tests) were used to compare the clinical data 
and CBA titers among the groups of patients. The categorical data from the study were 
analyzed using Fisher’s exact test, and p < 0.05 was considered to be significant. 
 
3.5 Standard protocol approvals, registration and patient consent.  
This study was approved by the Ethics Committee of each center and 
conducted in accordance with internationally recognized ethical standards. All of the 
study participants provided written informed consent. 
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4. RESULTS 
 
In total, 215 patients with NMOSD were included: 152 from Brazil (Hospital 
das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, University of 
Sao Paulo, Sao Paulo and CIEM Multiple Sclerosis Research Center at Federal 
University of Minas Gerais, Belo Horizonte) and 63 from Japan (Tohoku University 
Hospital, Tohoku University School of Medicine, Sendai). Among these patients, 7.4% 
(16/215) were positive for MOG antibodies, 64.7% (139/215) were positive for AQP4 
antibodies and the remaining 27.9% (60/215) were seronegative. No patients were 
positive for both antibodies. Patients with MOG antibodies represented 21.1% (16/76) 
of AQP4-antibody seronegative cases. All serological groups were found in each center, 
and there were no clear differences based on the ethnicity as declared per each patient.  
The clinical characteristics of each patient with MOG antibodies are 
summarized in Table 2. None of the patients had encephalopathy or seizures usually 
required for the diagnosis of ADEM. In the acute phase, all patients with MOG 
antibodies received intravenous high-dose methylprednisolone (1 g/day for 3 – 5 days) 
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as the first-line treatment for acute attacks, and 87.5% (14/16) of them experienced 
good recovery after treatment. Only one patient with a severe LETM attack, with 
tetraparesis, urinary retention, and a sensory level of Th10 and below, was further 
treated with five sessions of plasmapheresis. However, this patient had only a partial 
recovery of motor strength in the trunk and upper limbs, remaining paraplegic and 
without bowel/bladder control.  
The median (range) MOG antibody titers were higher in patients with a 
single-attack than in recurrent patients (4,096 [128 – 32,768]) vs. 384 [128 – 4,096]), 
respectively, p = 0.0193), suggesting that some patients may have a significant decrease 
in the MOG antibodies over time. However, persistent positivity for MOG antibodies 
was confirmed in consecutive samples (after treatment) from seven patients after a 
median (range) of 246 (34 – 400) days, and the median (range) of MOG antibody titers 
was 4,096 (256 – 16,384) on the first sample and 1,024 (256 – 16,384) on the follow-up 
sample (p = 0.5). 
  
4.1 Comparison of demographic and main clinical syndrome features according to 
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antibody status 
Among the patients, 168 were female and 47 were male. The female:male 
ratio was 7.2:1.0 (122/17) in the AQP4 antibody group and 2.0:1.0 (40/20) in the 
seronegative group. By contrast, males predominated (ratio of 0.6:1.0 [6/10]) in the 
group of patients with MOG antibodies. The median (range) onset age was 37.5 (3 – 70) 
years for patients with MOG antibodies, 37 (4 – 78) years for patients with AQP4 
antibodies and 32.5 (10 – 69) for patients who were seronegative for both antibodies (p 
= 0.0915). 
In the group of patients who met the criteria for definite NMO by the 
Wingerchuk 2006 revised criteria (n = 101), only one patient had MOG antibodies, 
whereas the majority had AQP4 antibodies (84.2% [85/101]) and 14.8% (15/101) were 
seronegative. Twelve patients with a single-attack who presented initially with optic 
neuritis and myelitis (occurring simultaneously or sequentially within 30 days), thus 
fulfilled the definitive NMO criteria in the first attack. Among them, one patient had 
MOG antibodies, eight had AQP4 antibodies, and three were seronegative for both 
antibodies.  
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In the group of patients with only LETM, 6.4% (5/78) had MOG antibodies, 
55.1% (43/78) had AQP4 antibodies, and 38.5% (30/78) were seronegative for both 
antibodies. Among the patients with bilateral simultaneous and/or recurrent ON, 27.8% 
(10/36) had MOG antibodies, 30.5% (11/36) had AQP4 antibodies, and 41.7% (15/36) 
were seronegative for both antibodies. 
The comparison of the demographic and clinical characteristics among 
patients with MOG antibodies, patients with AQP4 antibodies, and those seronegative 
for both antibodies is summarized in Table 3 and 4. 
 
4.2 Comparison of detailed clinical features among patients with MOG and AQP4 
antibodies and seronegatives 
In total, 155 patients were positive for either MOG or AQP4 antibodies. 
Brainstem symptoms commonly reported in AQP4 antibody-positive patients, such as 
persisting nausea/vomiting episodes for longer than 48 hours, were found in 40.6% 
(56/139) of patients with AQP4 antibodies, whereas only a single patient with MOG 
antibodies and 11.7% (7/60) of the seronegative patients reported similar symptoms 
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during attacks (p < 0.0001). Intractable hiccups were only reported in patients with 
AQP4 antibodies and one seronegative patient (0 [0/16] vs. 23.7% [33/139] vs. 1.7% 
[1/60] for patients with MOG antibodies, patients with AQP4 antibodies, and 
seronegative patients, respectively; p <0.0001). Painful tonic spasms were present in 
6.3% (1/16) of the patients with MOG antibodies, 42.5% (59/139) of the patients with 
AQP4 antibodies, and 31.7% (19/60) of seronegative patients (p = 0.0073). 
Among patients with ON attacks, 18.8% (3/11) of the MOG antibody group, 
72.9% (72/96) of the AQP4 antibody group, and 46.7% (14/30) of the seronegative 
group had a visual acuity < 20/200 at the last follow-up (p = 0.0010). One patient 
(9.1%) positive for MOG antibodies, 30.2% (29/96) of the patients positive for AQP4 
antibodies, and 13.3% (4/30) of the seronegative patients had no light perception after 
an ON attack. Bilateral, simultaneous ON attacks were observed in all groups, but such 
attacks were more common in patients with MOG antibodies (see illustrative imaging 
scan in Figure 5) than in those with AQP4 antibodies or those who were seronegative 
(72.7% [8/11] vs. 24.0% [23/96] vs. 36.7% [11/30], respectively; p = 0.0035). 
Patients with a single-attack comprised 50.0% (8/16) of patients with MOG 
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antibodies and 16.6% (23/139) of patients with AQP4 antibodies (p = 0.0044). In these 
patients, the median (range) follow-up was not different among patients with MOG 
antibodies, those with AQP4 antibodies, and those who were seronegative (1 [1 – 19] vs. 
2 [1 – 27] vs. 1 [0 – 11] years, respectively; p = 0.3046). The median disability at the 
last visit after a single attack measured by the Expanded Disability Status Score (EDSS) 
was 2 (range: 0-5) in the MOG antibody-positive group, 6 (2 – 8.5) in the AQP4 
antibody-positive group, and 4.5 (0 – 7) in the seronegative group (p = 0.0173). 
Recurrent patients with MOG antibodies (n = 8) had a median follow-up of 
4.5 years (range: 2 – 18), in contrast to 8 years (range: 0 – 45) in the patients with AQP4 
antibodies and 3 years (range: 0 – 32) in seronegative patients (p = 0.0046), but there 
were no differences between patients with MOG and AQP4 antibodies (p = 0.1493) or 
between patients with MOG antibodies and those who were seronegative (p = 0.5399). 
Recurrent patients who were positive for MOG antibodies had a lower median number 
of attacks than patients positive for AQP4 antibodies and those who were seronegative 
(2 [2 – 3] vs. 4 [2 – 33] vs. 3 [2 – 18], p = 0.0011), most likely because of the higher 
median (range) number of myelitis attacks in the patients with AQP4 antibodies and in 
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those who were seronegative (0 [0 – 2] vs. 2 [0 – 30] vs. 2 [0 – 15], respectively; p = 
0.0026). However, the annual relapse rate was not different among recurrent disease 
patients with MOG antibodies (0.5 [0.1 – 1]), those with AQP4 antibodies (0.7 [0.1 – 
4]), and those who were seronegative for both antibodies (0.9 [0.1 – 4]) (p = 0.1453). 
The median (range) EDSS at the last visit of the patients with recurrent disease was 1.5 
(1 – 8) in patients with MOG antibodies, 5.5 (1 – 8.5) in patients with AQP4 antibodies, 
and 4 (1 – 7) in seronegative patients (p = 0.0125). Therefore, patients with MOG 
antibodies clearly appear to have a better outcome regardless of the course (single or 
recurrent) of the disease. 
 
4.3 Comparison of MRI findings among patients with MOG antibodies, AQP4 
antibodies or seronegatives 
An abnormal brain MRI was present in 37.5% (6/16) of patients with MOG 
antibodies, 56.8% (79/139) of patients with AQP4 antibodies, and 56.7% (34/60) of 
patients who were seronegative for both antibodies. Medullary lesions commonly 
associated with persisting nausea/vomiting or hiccups episodes in NMOSD were 
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observed in a single patient with MOG antibodies, in 12.9% (18/139) of patients with 
AQP4 antibodies, and in 3.3% (2/60) of patients who were seronegative for both 
antibodies.  
Spinal cord lesions on MRI were present in 37.5% (6/16), 92.1% (128/139), 
and 71.7% (43/60) of patients with MOG antibodies, patients with AQP4 antibodies, 
and seronegative patients, respectively (Table 5 and 6). Lesions in patients with MOG 
antibodies were distributed more frequently in the thoraco-lumbar region, sometimes 
extending to the conus medullaris (see figure 6). By contrast, patients with AQP4 
antibodies and those seronegative had more lesions distributed in the cervico-thoracic 
region. All patients with MOG antibodies (6/6), all patients who were seronegative for 
both antibodies (43/43), and 89.1% (114/128) of patients with AQP4 antibodies had 
lesions covering three or more vertebral segments in the sagittal spinal cord MRI. The 
median (range) number of vertebral segments of the longest spinal cord lesion was 6.5 
(3 – 14) in patients with MOG antibodies, 6 (1 – 19) in patients with AQP4 antibodies, 
and 4.5 (3 – 19) in seronegative patients (p = 0.3658). The involvement of the central 
portion of the spinal cord in the axial spinal cord MRI was found in 66.7% (4/6) of 
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patients with MOG antibodies, 89.8% (115/128) of patients with AQP4 antibodies, and 
79.1% (34/43) of those seronegative for both antibodies (p = 0.0721). 
 
4.4 Comparison of laboratory findings among patients with MOG antibodies, AQP4 
antibodies or seronegatives 
Analysis of the CSF was available in 73.4% (158/215) of the patients, but 
there were no differences on the general CSF analysis results and frequency of 
oligoclonal IgG bands between the three groups. Antinuclear autoantibodies (ANA) in 
the serum were found less frequently in patients with MOG antibodies than in the other 
groups. The frequency of other antibodies was not different among the three groups, but 
not all patients have results available for all antibodies (Table 5). 
 
4.5 Comparison of long-term treatments used in patients with MOG antibodies, AQP4 
antibodies or seronegatives 
Among the patients with MOG antibodies, 56.3% (9/16) were on oral 
corticosteroids for relapse prevention, whereas oral corticosteroids were used by 80.6% 
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(112/139) of patients with AQP4 antibodies and 56.7% (34/60) of patients who were 
seronegative (p = 0.0007). Azathioprine was used in 25.0% (4/16) of patients with 
MOG antibodies, 54.7% (76/139) of patients with AQP4 antibodies, and 38.3% (23/60) 
of patients who were seronegative (p = 0.0166). A single patient with MOG antibodies, 
8.6% (12/139) of patients with AQP4 antibodies, and 3.3% (2/60) of seronegative 
patients used mitoxantrone. None of the patients with MOG antibodies, 8.6% (12/139) 
of the patients with AQP4 antibodies, and only one seronegative patient used rituximab 
(anti-CD20 that causes B cell depletion). None of the patients included in this study 
received tocilizumab (anti-interleukin-6 receptor blocker) or eculizumab (monoclonal 
antibody that inhibits the cleavage of C5 to C5a). 
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5. DISCUSSION 
 
In this study, the clinical features of patients who received a clinical diagnosis 
of NMOSD with MOG antibodies were compared to those with AQP4 antibodies, and 
also with those patients who were seronegative to both antibodies. Patients with MOG 
antibodies tended to have a single or a lower number of attacks, whereas patients with 
AQP4 antibodies were more likely to be prototypical NMO patients, with a relapsing 
disease characterized by severe ON and LETM attacks, as previously described1). The 
degree of recovery, measured by EDSS and visual acuity, also indicates that patients 
with MOG antibodies tended to have a better recovery after an attack. Kitley et al 36) 
recently published very similar results comparing patients with AQP4 and MOG 
antibodies seen at Oxford University, indicating a consistency of clinical features of 
these patients with MOG antibodies among independent cohorts. Nevertheless, it is 
important to emphasize that some patients with MOG antibodies experience severe 
disability after ON or LETM attacks, and thus few patients in this group may not always 
recover well. 
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The study results suggest that patients with MOG antibodies fulfilling the 
definitive NMO criteria as recently reported26) may vary depending among cohorts of 
patients due to differences on the referral systems from each center. Some NMOSD 
cases with MOG antibodies reported previously (Table 7) and the single NMO case in 
this study had a monophasic presentation with both ON and myelitis occurring during 
the same attack (interval of few days), similarly to the original case described by Devic 
in 1894. In fact, some of these patients with MOG antibodies and single attack in the 
previous and current studies may have a spatially limited form of ADEM but without 
encephalopathy and typical brain lesions, which could mimic NMOSD. However, 
recurrent patients with persistent MOG antibodies after several months were also found 
as recently described37), which is not usually observed in ADEM patients and precludes 
the generalization of this hypothesis to all patients. 
The strong female predominance in patients with AQP4 antibodies was not 
found in the MOG antibody group, and a much lower female:male ratio was found in 
seronegative patients. A similar difference in the female:male ratio between the diseases 
(with MOG antibodies and with AQP4 antibodies) was observed in previous small scale 
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studies26, 35) and this finding seems to parallel the serum ANA positivity. By contrast, 
and similarly to MOG antibody mediated disease, ADEM does not appear to have a sex 
bias.38) The difference on the gender distribution is reproduced in some studies that 
compared AQP4 antibody positive patients and seronegatives, especially those ones that 
used highly sensitive AQP4 assays39-41), but the patients with MOG antibodies were not 
segregated from those seronegative for both antibodies. The lack of female 
predominance in the group of patients with MOG antibodies resembles the case series 
described by Gault, more than 100 years before the AQP4 antibody discovery.  
There was a difference in the spatial distribution of spinal cord lesions on 
MRI between patients with MOG antibodies and those with AQP4 antibodies. The 
patients with AQP4 antibodies frequently had cervical lesions, including some 
extending to the medullary region, whereas patients with MOG antibodies more 
frequently had long lesions extending to the lumbar spinal cord and conus medullaris. 
Consistent with the lesion localization in the caudal portion of the spinal cord, many 
patients with MOG antibodies frequently have sensory impairment and urinary 
dysfunction. Curiously, such lesions seen to have some parallel to the lesions observed 
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in some EAE models using MOG antigens that develop a NMO-like disease. 
Brainstem symptoms, such as persistent nausea/vomiting and hiccups, as 
previously reported in NMOSD22, 42), were far more commonly found in the AQP4 
antibody group than in the MOG antibody or seronegative groups. Typical pathological 
NMO lesions with astrocyte injury (loss of GFAP and AQP4 staining), infiltration of 
inflammatory cells, IgG and complement deposition in the area postrema have been 
found in post-mortem specimens of AQP4 antibody-positive patients43), and, although 
no pathological studies have been performed on patients with MOG antibodies, no 
lesions in area postrema as seen in AQP4-antibody positive patients would be expected 
in this group.  
Although MOG antibodies have been shown to be potentially pathogenic and 
to efficiently activate complement in vitro, these antibodies have been reported in a 
variety of demyelinating diseases such as ADEM and MS, 33) especially in pediatric 
populations 44, 45) and now in NMOSD patients.35) It is possible that differences in 
antibody assays or cohort ascertainments have a role to play in the apparent non-disease 
specificity of the MOG antibodies. One could argue that the presence of MOG 
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antibodies in a number of distinct diseases may currently limit the use of the MOG 
antibody assay as a specific diagnostic biomarker, and it is possible that other 
undiscovered autoantibodies or distinct disease mechanisms may exist in the 
seronegative patients for both antibodies. However, it is important to consider that 
excluding the NMOSD patients with AQP4 antibodies, all of these diagnoses are 
currently based on clinical, and MRI features. Most of current knowledge about MOG 
antibodies is based on assays using denatured unfolded MOG protein or fragments, so 
the conclusions from early studies should be taken with some caution as they failed to 
identify meaningful subgroup of patients compared to the analysis using assays that can 
detect conformational sensitive MOG antibodies such as the cell-based assay used in 
this study. Because of the study design, patients with MOG antibodies who had 
received a diagnosis of ADEM and MS were not included in this study, so the study 
findings are currently limited to patients who received a diagnosis of NMOSD. We have 
tested some patients with consecutive samples, but additional studies regarding the 
change on MOG antibody titers throughout a longer time spam are required. Another 
limitation is that ethnicity from Brazilian patients is very heterogeneous with a high rate 
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of admixture, and the genetic features of each ethnicity that may increase the risk of 
developing autoimmunity were not analyzed in this study. Further studies evaluating the 
recognition of MOG epitopes and pathogenicity by these antibodies including a broader 
number of inflammatory idiopathic CNS disorders, such as MS, ADEM, AQP4 
antibody seronegative NMOSD, and isolated optic neuritis may clarify whether patients 
with MOG antibodies may have a common immunopathological mechanism. 
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6. CONCLUSIONS 
 
MOG-antibody positive patients, regardless of whether they had a single 
attack or recurrent disease, had some distinct clinical presenting features, had usually 
fewer attacks and had a better recovery after an attack than patients with AQP4 
antibodies or those seronegative for both antibodies. These findings suggest that 
immune mechanisms involved in each of those groups may be distinct, with 
demyelination on patients with MOG antibodies and immune-mediated astrocyte injury 
in patients with AQP4 antibodies. Therefore, the long-term management of patients 
with MOG antibodies may be different from those with AQP4 antibodies. Additional 
studies may confirm the ability of conformational specific MOG antibodies found in 
those patients diagnosed as NMOSD to promote efficient demyelination with absence 
of immune-mediated astrocyte injury. Further prospective studies are required to 
investigate whether patients with a single attack and recurrent patients with MOG 
antibodies - with clinical diagnosis of ADEM, MS or NMOSD - have a singular 
immune-mediated demyelinating disease with some differences in the clinical 
presentation, but with a similar disease course and treatment response.  
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8. TABLES 
 
Table 1: Definitions of neuromyelitis optica (NMO) before the discovery of AQP4 antibody. Adapted from Sato et al (2013)8). 
Author Year of 
publication 
Interval between 
optic neuritis and 
myelitis 
Myelitis Optic neuritis Other CNS Involvement: 
clinical 
Other CNS 
Involvement; 
subclinical 
Relapses 
McAlpine 1938 Up to several 
months 
Acute or subacute Acute, bilateral No (in principle) Mild lesions or 
none 
Yes 
Cloys 1970 No limitation Acute or subacute Acute or subacute, uni 
or bilateral 
Yes Yes Yes 
Devic M 1980 NA ATM Acute, bilateral NA Yes No 
Kuroiwa 1975, 1985 ≤ 4 weeks ATM Acute, bilateral Minor signs Yes (rare) No 
Leys 1987 Up to 3 years Acute (≤4 weeks) Uni or bilateral No Yes Corticosteroid 
dependent only 
Silber 1990 Within 3 months Acute (≤ 2 weeks) Acute, uni or bilateral No No (except 
medulla) 
No 
Mandler 1993, 1998 Up to several 
years 
Acute (or 
subacute?) 
Acute, uni or bilateral No No (except 
medulla) 
Yes 
Fazekas 1994 NA Acute or subacute Acute or subacute No No Yes 
O’Riordan 1996 Up to 5 years Acute ≤ 2 weeks Uni or bilateral, acute No Yes Yes 
Vernant 1997 NA Acute or subacute Uni or bilateral Hypothalamic-hypophyseal signs 
and lesions 
 Yes 
Baudoin 1998 Within several 
months 
ATM (subacute 
myelitis possible) 
Acute, bilateral No (in principle), but brainstem, 
cerebellar and visual pathway 
lesions were seen 
 No 
Wingerchuk 1999 (Up to 2 years) Acute Uni or bilateral No Yes Yes 
Legends: CNS = central nervous system; ATM: acute transverse myelitis, NA: information was not available  
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Table 2: Clinical characteristics of 16 NMO spectrum disorder patients with MOG antibodies 
Patient 
No. 
Onset age 
(years) / 
Gender 
Disease 
duration 
(years) 
Number 
of 
attacks 
Phenotype First attack site 
Severe 
visual 
disability 
BS 
symptoms EDSS Brain MRI Spinal MRI lesion 
CSF 
cell 
counts 
CSF 
protein 
(mg/dl) 
CSF 
OCB 
Other serum 
autoantibodies 
MOG 
antibody 
titer (1:x) 
Treatment 
1 30/ M 2 2 LETM Thoracic myelitis N/A YES 8.0 T2-hyperintensity surrounding 3
rd and 
4th ventricules Th3 - conus 7 164 Negative Negative 1:256 
CS, AZA, 
mitoxantrone 
2 37 / F 19 1 NMO Bilateral ON + myelitis YES NO 5.0 Non-specific WM lesions Th8 – Th10 N/D N/D N/D Negative 1:128 None 
3 34 / M 9 3 Recurrent ON Left ON NO NO 2.0 Normal N/A N/D N/D N/D Negative 1:4,096 None 
4 24 / M 1 1 Bilateral ON Bilateral simultaneous ON YES NO 3.0 Non-specific WM lesions N/A 5 27 Negative Negative 1:4,096 None 
5 46 / F 5 2 Recurrent ON Left ON NO NO 1.0 Normal N/A 45 38 N/D Negative 1:512 CS 
6 29 / M 1 1 LETM Thoracic myelitis N/A NO 3.0 Normal Th7 - conus 154 34 N/D TgAb+ 1:4,096 CS, AZA 
7 3 / F 3 3 LETM Cervical myelitis N/A NO 5.0 
T2-high subcortical lesions in the 
right frontal lobe, bilateral occipital 
and right cerebellar peduncle 
C2 – C5, Th2 – 
Th6, and Th10 - 
conus 
21 34 Negative Negative 1:1,024 None 
8 15 / F 18 3 Recurrent ON Right ON NO NO 1.0 Non-specific WM lesions N/A 3 30 Negative ANA+ 1:256 AZA 
9 40 / M 1 1 Bilateral ON Bilateral simultaneous ON NO NO 1.0 Normal N/A 3 49 N/D Negative 1:16,384 CS, AZA 
10 50 / M 5 2 LETM Thoracolumbar myelitis N/A NO 6.0 Normal Th1 – conus 30 28 Negative Negative 1:256 CS 
11 49 / M 2 1 LETM Thoracolumbar myelitis N/A NO 3.5 Normal Th7 – Th9 125 39 Negative ANA+ 1:32,768 None 
12 28 / M 1 1 Bilateral ON Bilateral simultaneous ON NO NO 0.0 Normal N/A N/D N/D N/D Negative 1:4,096 CS 
13 70 / M 1 1 Bilateral ON Bilateral simultaneous ON NO NO 0.0 Normal N/A N/D N/D N/D SSA+ 1:16,384 CS 
14 38 / M 1 1 Bilateral ON Bilateral simultaneous ON NO NO 1.0 Non-specific WM lesions N/A N/D N/D N/D TPOAb+ 1:2,048 CS 
15 45 / F 4 2 Recurrent ON Left ON NO NO 1.0 Normal N/A N/D N/D N/D Negative 1:128 CS 
16 47 / F 2 2 Recurrent ON Right ON NO NO 1.0 Non-specific WM lesions N/A 1 39 N/D Negative 1:512 None 
Footnotes: LETM = longitudinally extensive myelitis; Severe visual disability was defined as visual acuity of 20/200 or less in one or both eyes at last follow up; BS = brainstem; EDSS = Expanded Disability Status Scale at last follow-up; 
OCB = oligoclonal bands; NMO = neuromyelitis optica; ON = optic neuritis; ANA = anti-nuclear antibody; SSA = anti-SSA antibody (anti-Ro); TGAb = anti-thyroglobulin antibody; TPOAb = thyroperoxidase antibody; WM = white 
matter; N/A = Not applicable; N/D = Not done; CS = Oral corticosteroids; AZA = Azathioprine. 
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Table 3 – Comparison of clinical features between NMOSD patients with MOG antibodies (MOG-Abs+), AQP4 antibodies 
(AQP4-Abs+) and those seronegative. 
 
Characteristic MOG-Abs+ 
(n = 16) 
AQP4-Abs+ 
(n = 139) 
Seronegative 
(n = 60) 
p value 
Phenotype, n (%)     
NMO 1/16 (6.3%) 85/139 (61.1%) 15/60 (25.0%)  
NMOSD-LETM 5/16 (31.2%) 43/139 (30.9%) 30/60 (50.0%) <0.0001 
NMOSD-ON 10/16 (62.5%) 11/139 (8.0%) 15/60 (25.0%)  
     
Female sex, n (%) 6/16 (37.5%) 122/139 (87.8%) 40/60 (66.7%) <0.0001 
Age, median (range), years     
at first attack 37.5 (3 – 70) 37 (4 – 78) 32.5 (10 – 69) 0.0915 
at sampling 42 (6 – 70) 49 (15 – 82) 38 (12 – 69) 0.0004 
Follow-up, median (range), years 2 (1 – 19) 7 (0 – 45) 3 (0 – 32) 0.0002 
     
Patients with a single attack, n (%) 8 (50.0%) 23 (16.6%) 18 (30.0%) 0.0031 
Simultaneous ON + myelitis attacks (any time) 1 (6.25%) 32 (23.0%) 6 (10.0%) 0.0406 
Number of attacks, median (range) 1.5 (1 - 3) 4 (1 – 33) 2.5 (1 – 18) <0.0001 
EDSS, median (range) 1.5 (0 – 8) 5.8 (1 – 8.5) 4 (0 – 7) <0.0001 
Legend: NMOSD = neuromyelitis optica spectrum disorders; MOG = myelin oligodendrocyte glycoprotein; AQP4 = aquaporin-4; Abs = antibodies; NMO = 
neuromyelitis optica; LETM = longitudinally extensive transverse myelitis; ON = optic neuritis, EDSS = Expanded Disability Status Score. 
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Table 4 – Comparison of clinical features between NMOSD patients with MOG antibodies (MOG-Abs+), AQP4 antibodies 
(AQP4-Abs+) and those seronegative, with statistical analysis between two groups. 
 
Characteristic MOG-Abs+ 
(n = 16) 
AQP4-Abs+ 
(n = 139) 
Seronegative 
(n = 60) 
MOG-Abs+ vs.
 AQP4-Abs+  
p value 
MOG-Abs+ vs.
 Seronegative  
p value 
AQP4-Abs+ vs.
 Seronegative  
p value 
Phenotype, n (%)       
NMO 1/16 (6.3%) 85/139 (61.1%) 15/60 (25.0%)    
NMOSD-LETM 5/16 (31.2%) 43/139 (30.9%) 30/60 (50.0%) <0.0001 0.0181 <0.0001 
NMOSD-ON 10/16 (62.5%) 11/139 (8.0%) 15/60 (25.0%)    
       
Female sex, n (%) 6/16 (37.5%) 122/139 (87.8%) 40/60 (66.7%) <0.0001 0.0455 0.0012 
Age, median (range), years       
at first attack 37.5 (3 – 70) 37 (4 – 78) 32.5 (10 – 69) 0.7552 0.3358 0.0296 
at sampling 42 (6 – 70) 49 (15 – 82) 38 (12 – 69) 0.1597 0.3653 0.0001 
Follow-up, median (range), years 2 (1 – 19) 7 (0 – 45) 3 (0 – 32) 0.0143 0.8468 0.0002 
       
Patients with a single attack, n (%) 8 (50.0%) 23 (16.6%) 18 (30.0%) 0.0044 0.1498 0.0368 
Simultaneous ON + myelitis 
attacks (any time) 
1 (6.25%) 32 (23.0%) 6 (10.0%) 0.0406 1.0000 0.0323 
Number of attacks, median (range) 1.5 (1 - 3) 4 (1 – 33) 2.5 (1 – 18) <0.0001 0.0198 0.0020 
EDSS, median (range) 1.5 (0 – 8) 5.8 (1 – 8.5) 4 (0 – 7) <0.0001 0.0034 0.0126 
Legend: NMOSD = neuromyelitis optica spectrum disorders; MOG = myelin oligodendrocyte glycoprotein; AQP4 = aquaporin-4; Abs = antibodies; NMO = 
neuromyelitis optica; LETM = longitudinally extensive transverse myelitis; ON = optic neuritis, EDSS = Expanded Disability Status Score.  
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Table 5 – MRI and laboratory findings in the NMOSD patients with MOG-antibodies (MOG-Abs+), AQP4-antibodies (AQP4-Abs+) 
and those seronegative. 
 
 MOG-Abs+ 
(n = 16) 
AQP4-Abs+ 
(n = 139) 
Seronegative 
(n = 60) 
p value 
Normal brain MRI, n/total (%) 62.5% (10/16) 43.2% (60/139) 43.3% (26/60) 0.3736 
Spinal MRI lesion localization     
Cervical, n/total (%) 1/6 (16.7%) 89/128 (69.5%) 29/43 (67.4%) 0.0345 
Thoracic, n/total (%) 6/6 (100%) 87/128 (68.0%) 31/43 (72.1%) 0.2879 
Lumbar, n/total (%) 4/6 (66.7%) 5/128 (3.1%) 4/43 (9.3%) <0.0001 
CSF analysis     
Cell count, median (range) 14 (1 – 154) 6 (0 – 379) 3 (0 – 143) 0.1157 
Protein, median (range) mg/dl 36 (27 – 164) 34 (10 – 307) 37 (16 – 254) 0.9652 
Oligoclonal bands positivity, n/total (%) 0/6 (0.0%) 11/60 (18.3%) 3/13 (23.1%) 0.5917 
Other Serum Autoantibodies     
ANA, n/total (%) 1/15 (6.7%) 46/107 (43.0%) 6/41 (14.6%) 0.0002 
Anti-SSA, n/total (%) 1/14 (7.14%) 19/100 (19.0%) 3/36 (8.3%) 0.2850 
Anti-SSB, n/total (%) 0/14 (0.0%) 9/100 (9.00%) 1/35 (2.9%) 0.4968 
TGAb, n/total (%) 1/11 (9.1%) 13/81 (15.2%) 1/15 (6.7%) 0.7185 
TPOAb, n/total (%) 1/11 (9.1%) 10/85 (11.8%) 0/19 (0.0%) 0.2939 
Legend: MRI = magnetic resonance imaging; NMOSD = neuromyelitis optica spectrum disorders; MOG = myelin oligodendrocyte glycoprotein; AQP4 = 
aquaporin-4; Abs = antibodies; CSF = cerebrospinal fluid; ANA = antinuclear antibodies; anti-SSA = anti-Sjögren's syndrome A antibodies; anti-SSB = 
anti-Sjögren's syndrome B antibodies; TGAb = thyroglobulin antibodies; TPOAb = thyroid peroxidase antibodies  
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Table 6 – MRI and laboratory findings in the NMOSD patients with MOG-antibodies (MOG-Abs+), AQP4-antibodies (AQP4-Abs+) 
and those seronegative, with statistical analysis between two groups. 
 MOG-Abs+ 
(n = 16) 
AQP4-Abs+ 
(n = 139) 
Seronegative 
(n = 60) 
MOG-Abs+ vs.
 AQP4-Abs+  
p value 
MOG-Abs+ vs.
 Seronegative  
p value 
AQP4-Abs+ vs.
 Seronegative  
p value 
Normal brain MRI, n/total (%) 62.5% (10/16) 43.2% (60/139) 43.3% (26/60) 0.2915 0.2598 0.7581 
Spinal MRI lesion localization       
Cervical, n/total (%) 1/6 (16.7%) 89/128 (69.5%) 29/43 (67.4%) 0.0146 0.0269 0.8496 
Thoracic, n/total (%) 6/6 (100%) 87/128 (68.0%) 31/43 (72.1%) 0.1769 0.3142 0.7048 
Lumbar, n/total (%) 4/6 (66.7%) 5/128 (3.1%) 4/43 (9.3%) 0.0001 0.0043 0.2314 
CSF analysis       
Cell count, median (range) 14 (1 – 154) 6 (0 – 379) 3 (0 – 143) 0.1331 0.0499 0.2226 
Protein, median (range) mg/dl 36 (27 – 164) 34 (10 – 307) 37 (16 – 254) 0.7641 0.8774 0.9793 
Oligoclonal bands positivity, n/total (%) 0/6 (0.0%) 11/60 (18.3%) 3/13 (23.1%) 0.5788 0.5170 0.7048 
Other Serum Autoantibodies       
ANA, n/total (%) 1/15 (6.7%) 46/107 (43.0%) 6/41 (14.6%) 0.0087 0.6607 0.0011 
Anti-SSA, n/total (%) 1/14 (7.14%) 19/100 (19.0%) 3/36 (8.3%) 0.4580 1.0000 0.1884 
Anti-SSB, n/total (%) 0/14 (0.0%) 9/100 (9.00%) 1/35 (2.9%) 0.5981 1.0000 0.4528 
TGAb, n/total (%) 1/11 (9.1%) 13/81 (15.2%) 1/15 (6.7%) 1.0000 1.0000 0.4573 
TPOAb, n/total (%) 1/11 (9.1%) 10/85 (11.8%) 0/19 (0.0%) 1.0000 0.3667 0.2018 
Legend: MRI = magnetic resonance imaging; NMOSD = neuromyelitis optica spectrum disorders; MOG = myelin oligodendrocyte glycoprotein; AQP4 = 
aquaporin-4; Abs = antibodies; CSF = cerebrospinal fluid; ANA = antinuclear antibodies; anti-SSA = anti-Sjögren's syndrome A antibodies; anti-SSB = 
anti-Sjögren's syndrome B antibodies; TGAb = thyroglobulin antibodies; TPOAb = thyroid peroxidase antibodies  
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Table 7 – Comparison of NMOSD patients’ characteristics between published studies and the current study with MOG antibodies 
Study Mader et al. 201135) 
(n = 10) 
Kitley et al 201226) 
(n = 4) 
Kitley et al 201436) 
(n = 9*)  
This study 
(n = 16) 
Onset age, median (range), years 41 (2 – 56) 29.5 (16 – 34) NA** 37.5 (3 – 70) 
Female Sex, n/total (%) 7 (70.0%) 1 (25.0%) 4 (44.4%) 6 (37.5%) 
Phenotype, n/total (%)     
NMO 3/10 (30.0%) 3/4 (75.0%) 4 (44.4%) 1/16 (6.3%) 
NMOSD – LETM 2/10 (20.0%) 1/4 (25.0%) 3 (33.3%) 5/16 (31.2%) 
NMOSD – ON 5/10 (50.0%) - 0 10/16 (62.5%) 
     
Monophasic patients, n/total (%) 2/10 (20.0%) 3/4 (75.0%) 9 (100%) 8/16 (50.0%)  
N. of attacks, median (range) 2.5 (1 – 16) 1 (1 – 2) 1 (1) 1.5 (1 – 3) 
     
Abnormal Brain MRI, n/total (%) 0/9 (0.0%) 2/4 (50.0%) 6 (66.6%) 6/16 (37.5%) 
Distribution of the Spinal MRI lesions     
Cervical, n/total (%) N.A. 2/4 (50.0%) 6/9 (66.7%) 1/6 (16.7%) 
Thoracic, n/total (%) N.A. 4/4 (100%) 8/9 (88.9%) 6/6 (100%) 
Lumbar, n/total (%) N.A. 1/4 (25.0%) 6/8 (75.0%) 4/6 (66.7%) 
MOG-antibodies titers (1:x) 2,560 (160 – 5,120) 60 (20 – 350) NA 1,536 (128 – 32,768) 
Legend: NMOSD = neuromyelitis optica spectrum disorders; MOG = myelin oligodendrocyte glycoprotein; NMO = neuromyelitis optica; LETM = longitudinally 
extensive transverse myelitis; ON = optic neuritis; MRI = magnetic resonance imaging; NA = not available. *Among the 9 patients included, 3 were from the 
previous study published on 2012. ** Only mean (32.3 years) and standard deviation (17.1) is available. 
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9. FIGURES 
 
FIGURES TITLES AND LEGENDS 
 
Figure 1. Clinical diagnosis of neuromyelitis optica (NMO), NMO spectrum disorders 
(NMOSD) and the positivity for antibodies against aquaporin-4 (AQP4). The diagnosis 
of NMO requires the presence of optic neuritis and myelitis, so patients with attacks 
restricted to one site (optic neuritis or myelitis) are usually known as NMOSD. The 
AQP4 antibodies are found predominantly in NMO/NMOSD patients, but the positivity 
is not an absolute criteria for the diagnosis of NMO / NMOSD. Moreover, there are 
patients that are AQP4 antibody positive that do not fill the current diagnostic criteria 
(e.g. cases with lesions restricted to brain/brainstem, unilateral monophasic optic 
neuritis, and short myelitis). Another subgroup is composed by the AQP4 antibody 
negative patients that can fulfill the current diagnostic criteria for NMO / NMOSD. 
 
Figure 2. Antibodies against aquaporin-4 (AQP4) and the cascade of events leading to 
astrocyte death. AQP4 antibodies bind to AQP4 richly expressed in the foot processes 
of astrocytes. Brain blood-barrier breakdown promotes leakage of antibodies to the 
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central nervous system (CNS), migration of inflammatory cells, and pro-inflammatory 
cytokine secretion. The binding of antibodies to AQP4 induces complement activation 
and the formation of membrane attack complex. More inflammatory cells are recruited 
to the lesion site and the combination of antibody-mediated cytotoxicity (includes 
complement activation) and direct cell-mediated cytotoxicity causes astrocyte injury 
and death. 
 
Figure 3. The myelin shealth produced by oligodendrocytes and antibodies against 
myelin oligodendrocyte glycoprotein (MOG). The most important disease-related 
proteins are shown (upper right). MOG antibodies may cause inflammation and 
demyelination, but other environmental factors may increase microglial/macrophage 
activation and axonal degeneration or migration of oligodendrocyte precursor cells 
(OPC) and remyelination. 
 
Figure 4. Indirect immunofluorescence staining with MOG-transfected cells showing 
localization of anti-human Immunoglobulin-G Alexafluor-488 (green) secondary 
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antibody in the membrane and ds-red2 (red) in the cytosol by confocal microscopy. 
Abbreviations: MOG = myelin oligodendrocyte glycoprotein 
 
Figure 5. Bilateral Optic Neuritis in a patient with MOG-antibodies. Axial STIR (short 
tau inversion recovery) and T1-weighted with gadolinium MRI of the optic nerves from 
a 28 years-old male patient with bilateral simultaneous optic neuritis and MOG 
antibodies (titer 1:4,096) shows bilateral STIR hyperintense lesions with contrast 
enhancement.  
Abbreviations: MOG = myelin oligodendrocyte glycoprotein; MRI = magnetic resonance imaging. 
 
Figure 6. Recurrent longitudinally extensive transverse myelitis in a patient with MOG 
antibodies. Sagittal T2-weighted MRI of the spinal cord from a 6 years-old female 
patient with recurrent longitudinally extensive transverse myelitis and MOG antibodies 
(titer 1:1,024) shows two longitudinally extensive lesions. On T1-weighted sagittal 
sequence, the lesion in the thoraco-lumbar transition shows a ring contrast 
enhancement. 
  54 
Abbreviations: MOG = myelin oligodendrocyte glycoprotein; MRI = magnetic resonance imaging. 
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